CN1283303C - Medicine composition for ischemia apoplexy - Google Patents
Medicine composition for ischemia apoplexy Download PDFInfo
- Publication number
- CN1283303C CN1283303C CNB021535159A CN02153515A CN1283303C CN 1283303 C CN1283303 C CN 1283303C CN B021535159 A CNB021535159 A CN B021535159A CN 02153515 A CN02153515 A CN 02153515A CN 1283303 C CN1283303 C CN 1283303C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine composition
- pharmaceutical composition
- fel ursi
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 208000006011 Stroke Diseases 0.000 title abstract description 9
- 206010008190 Cerebrovascular accident Diseases 0.000 title abstract description 8
- 208000028867 ischemia Diseases 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title description 16
- 239000000843 powder Substances 0.000 claims abstract description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 17
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 241000305492 Gastrodia Species 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 14
- 206010008118 cerebral infarction Diseases 0.000 claims description 10
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine composition for ischemia apoplexy and a preparation method thereof. The medicine composition for ischemia apoplexy uses bear gall powder, notoginseng, gastrodia tubers, red sage roots, tabasheer and wine treated rhubarb as raw materials. According to the different characteristics of the traditional Chinese medicines, the medicine composition for ischemia apoplexy is prepared through pulverization, solvent extraction, concentration, uniform mixing, etc. The present invention has the advantages of peculiar pharmaceutical formulation and manufacturing method and obviously therapeutic effect.
Description
The present invention relates to treat the pharmaceutical composition of cerebral infarction, the pharmaceutical composition of acute cerebral ischemic stroke and convalescent care specifically the invention still further relates to the preparation method of this medicine.
Apoplexy sickness rate height, case fatality rate height, disability rate height, treatment difficulty.According to the relevent statistics, in China, the sickness rate of apoplexy has risen to 109.74/10 ten thousand, and prevalence is 245.58/10 ten thousand, and annual newfound stroke patient is about 1,320,000 people, about 3,000,000 people of number of patients.Mortality rate is 30～40%, and existent has 50～60% to leave sequela after being ill, mainly shows as obstacle of limb movement, aphasis, dysnoesia, has a strong impact on patient's ability to work and quality of life.This brings heavy burden not only for society and family, also brings very big misery to the patient.
Western medical treatment cerebral infarction means are limited in the market, lack the specific treatment medicine:
-still unsatisfactory as brain-protection drugs clinical efficacies such as excitatory amino acid receptor antagonists, free radical scavengers.
-early stage thrombolytic therapy is owing to the treatment time window, and the restriction of bringing out negative factors such as cerebral hemorrhage, has influenced the performance of its curative effect, and at present still can't be as conventional therapy at clinical application.
The objective of the invention is to develop with strong points, good effect, easy to use, safe, be suitable for acute cerebral ischemic stroke and convalescent new Chinese medicine.
Pharmaceutical composition of the present invention is mainly made by following component: (consumption is a weight portion)
Fel Ursi powder 0.3-10 Radix Notoginseng 4-130 Rhizoma Gastrodiae 20-640
Concretio Silicea Bambusae 10-385 Radix Salviae Miltiorrhizae 17-575 Radix Et Rhizoma Rhei (processed with wine) 7-255
The formula optimization weight portion ratio range of pharmaceutical composition of the present invention is:
Fel Ursi powder 0.5-2.5 Radix Notoginseng 6-32 Rhizoma Gastrodiae 32-160
Concretio Silicea Bambusae 20-200 Radix Salviae Miltiorrhizae 28-144 Radix Et Rhizoma Rhei (processed with wine) 12-64
Most preferably weight (part) proportioning of pharmaceutical composition of the present invention is:
Fel Ursi powder 1.3 Radix Notoginseng 16.7 Rhizoma Gastrodiaes 83.3
Concretio Silicea Bambusae 50 Radix Salviae Miltiorrhizaes, 75 Radix Et Rhizoma Rhei (processed with wine) 33.3
The present invention is the Chinese medicine expert for many years on the basis of apoplexy clinical experience, is guidance with the therapeutics thought of " heresy is gone to then Zhengan County ", is that principle of treatment plan side forms with eleminating phlegm and freeing channels, detoxifcation purging FU-organs.The Fel Ursi bitter in the mouth is cold in nature in the side, goes into liver, gallbladder, spleen, stomach warp.The suppressing the hyperactive liver that clears away heart-fire, " it is former that book on Chinese herbal medicine is asked " record Fel Ursi " is controlled blood-retention ", with being monarch drug, dispels the turbid poison of blood stagnant in cerebral venation syndrome.The Rhizoma Gastrodiae sweet in the mouth is flat, goes into Liver Channel, and with being ministerial drug, relieving dizziness, high fever, infantile convulsions, epilepsy, etc. and reduce phlegm, the clear sharp head, shared with Fel Ursi, help its removing toxic substances turbid merit of dispelling.Radix Notoginseng, sweet and slightly bitter taste, warm in nature, go into liver, stomach warp, blood circulation promoting and blood stasis dispelling, the analgesic therapy of invigorating blood circulation, with Rhizoma Gastrodiae be ministerial drug altogether, endogenous wind-evil caused by sthenic liver-energy) reduces phlegm, and helps eliminating evilization of Fel Ursi turbid, and turbid pathogen speed is gone, the venation of brain gets freely.The Concretio Silicea Bambusae sweet in the mouth, cold in nature, go into the heart, liver, gallbladder meridian.Removing heat-phlegm, the arresting convulsion that clears away heart-fire, with wind-phlegm fan in controlling, phlegm-accumulating vertigo helps the Fel Ursi Rhizoma Gastrodiae turbid power of dispelling of reducing phlegm.The Radix Salviae Miltiorrhizae bitter in the mouth, slightly warm in nature is gone into the heart, Liver Channel, blood circulation promoting and blood stasis dispelling, calming heart and tranquilizing mind, the power that helps the Radix Notoginseng blood stasis dispelling to promote blood circulation.The Radix et Rhizoma Rhei (stir-fried with wine) bitter in the mouth is cold in nature, goes into liver, stomach, large intestine channel, the poison that purges heat, and clots absorbing blood, expectorant is real, " Japan hanako materia medica " " logical all gas of a surname, blood circulation regulating, sharp joint ".All medicines and usefulness are changed turbid poison, promoting blood circulation, and it is wet to eliminate the phlegm, and puts out liver-wind, and merit is eliminating evil.Symptomatic treatment in acute condition, the gesture on the wind from the northwest being apt to impair the small intestine expectorant blood stasis, so that the brain arteries and veins is logical again, the brain key is recovered lost eyesight, all diseases of apoplexy must subtract.
Pharmaceutical composition of the present invention adopts routine techniques, adds conventional adjuvant or excipient, preferably make to be fit to oral dosage form, for example, granule, capsule, tablet and watered pill; Drug regimen of the present invention is preferably made injection, ointment, spray.
Its pharmacological tests of pharmaceutical composition provided by the present invention is:
(1) pharmacodynamic study:
Mainly study under the rat cerebral ischemia situation, this pharmaceutical composition is to the influence of indexs such as its nervous symptoms, time-to-live and cerebral infarction district vascular permeability, platelet aggregation time, thrombus formation time.
The result shows, the big-and-middle small dose group of this pharmaceutical composition (6g crude drug/kg, 3g crude drug/kg, 1.5g crude drug/kg) all have following effect:
Obviously alleviate the nervous symptoms after the focal cerebral ischemia in rats, reduce the cerebral infarction scope;
Obviously improve pathological change such as cerebrovascular permeability and brain water content increase due to the cerebral ischemia;
Obviously increase the dog cerebral blood flow, reduce cerebral vascular resistance, arteriotony and heart rate;
Platelet aggregation rate when obviously reducing focal cerebral ischemia in rats;
Obviously delay the animal thrombus formation time;
Obviously suppress rat suppository and form, alleviate the weight in wet base of artery-vein bypass thrombosis;
Obviously prolong the time-to-live of mice under the normal pressure resistant anoxia condition, increase mice normal pressure resistant anoxia ability;
Dehisce the time of breathing after obviously prolonging the mice broken end.
(2) anxious, long poison experiment:
1. anxious poison test: 48 mice fasting are after 12 hours, gastric infusion is three times in 24 hours, dosage is 60 gram crude drugs/kg/ time, accumulated dose was 180 gram crude drug/kg/ days, continuously observed mice 7 after the administration, index no abnormality seen such as general state, hair color, body weight, diet, activity and do not have death.
As calculated, this pharmaceutical composition mouse stomach maximum tolerated dose was 180 gram crude drug/kg/ days, was equivalent to 414.5 times of people's consumption.
2. long term toxication: laboratory observation this pharmaceutical composition continuous irrigation stomach 180 days body weight to rat, hematological indices, serum biochemistries learn index and main organs coefficient and histological influence.
Experimental result:
1. during administration, it is all normal that each organizes the behavior of rat outward appearance, body weight, food-intake; When routine blood test, blood coagulation all in the normal variation scope, biochemical indicator: comprise that liver function renal function etc. compared with corresponding matched group in 90 days, 180 days after administration, all in the normal variation scope, do not see notable difference.
2. the histoorgan organ index in administration two weeks after 90,180 days and after the drug withdrawal, outward appearance are observed and be there is no obvious pathologic and change.
The above results shows, this pharmaceutical composition 30g crude drug/kg, 15g crude drug/kg and 7.5g crude drug/kg successive administration no overt toxicity reaction in 6 months.
Embodiment 1: capsule
Prescription:
Fel Ursi powder 13g Radix Notoginseng 167g Rhizoma Gastrodiae 833g
Concretio Silicea Bambusae 500g Radix Salviae Miltiorrhizae 750g Radix Et Rhizoma Rhei (processed with wine) 333g
Production method: above Six-element, Fel Ursi powder are ground into fine powder I.Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei (processed with wine) add 8 times of amount 75% alcohol heating reflux at every turn and extract 4 times, and each 40 minutes, filter, merging filtrate reclaims ethanol, and medicinal liquid is concentrated into the thick paste II for future that relative density is 1.30～1.35 (60 ℃); Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae decoct with water 3 times, each 1 hour, amount of water is 8,6,6 times, filter, merging filtrate, filtrate decompression is concentrated into the thick paste II I that relative density is 1.30～1.35 (60 ℃), the thick paste that extracts with Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei merges, mixing, drying under reduced pressure, dried cream powder is broken into fine powder.Fel Ursi powder 12.5g, dried cream powder 279.5g and dextrin 108g mixing, drying is sieved, and incapsulates, promptly.
Embodiment 2: granule
Press example 1 described proportioning and technology with Fel Ursi powder I, Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei thick paste II, Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae thick paste II I and an amount of dextrin mix homogeneously, granule is sterilized, made to alcohol granulation, at cold drying.
Embodiment 3: tablet
Press example 1 described proportioning and technology with Fel Ursi powder I, Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei thick paste II, Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae thick paste II I and an amount of dextrin mix homogeneously, alcohol granulation, drying, compacting are in blocks.
Embodiment 4: the watered pill
By example 1 described proportioning and technology Fel Ursi powder I, Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei thick paste II, Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae thick paste II I and water are placed mixing in general ball pot or other container, make wet-milling, pressed No. two sieve series to become granule, again granule is put into the spin friction of general ball pot, wound goes corner angle circular, makes the watered pill.
Embodiment 5: injection
Press example 1 described proportioning and technology Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei thick paste II are mixed with Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae thick paste II I, pulverize behind the drying under reduced pressure, add solvent and make its dissolving; Fel Ursi powder I adds solvent makes its dissolving.Then two parts solution is mixed, add solvent to 1000ml, regulate pH value, filtration, perfusion, sealing by fusing, sterilization, quality inspection are promptly.
Embodiment 6: ointment
By example 1 described proportioning and technology Fel Ursi powder I, Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei thick paste II, Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae thick paste II I and an amount of dextrin mix homogeneously are ground to no granular sensation, gradation adds with in the substrate (as vaseline, tween 80, Polyethylene Glycol etc.) of melting, the limit edged is stirred to condensation, makes ointment.
Embodiment 7: spray
Press example 1 described proportioning and technology with Fel Ursi powder I, Rhizoma Gastrodiae, Radix Notoginseng, Radix Et Rhizoma Rhei thick paste II, Radix Salviae Miltiorrhizae, Concretio Silicea Bambusae thick paste II I and an amount of dextrin and suspending agent (as Arlacel-85) mixing after, being ground to particle diameter through colloid mill is that the following person of 5um accounts for more than 90%, add propellant (as dichlorodifluoromethane, noble gas etc.), press while stirring and irritate in molten device, make spray.
Claims (3)
1. pharmaceutical composition for the treatment of cerebral infarction, the raw materials of effective components medicine that it is characterized in that making medicine are formed:
Fel Ursi powder 0.5-2.5 Radix Notoginseng 6-32 Rhizoma Gastrodiae 32-160
Concretio Silicea Bambusae 20-200 Radix Salviae Miltiorrhizae 28-144 Radix Et Rhizoma Rhei 12-64.
2. pharmaceutical composition according to claim 1 is characterized in that the raw materials of effective components medicine composition of making medicine is by weight:
Fel Ursi powder 1.3 Radix Notoginseng 16.7 Rhizoma Gastrodiaes 83.3
Concretio Silicea Bambusae 50 Radix Salviae Miltiorrhizaes 75 Radix Et Rhizoma Rhei 33.3.
3. pharmaceutical composition according to claim 1 is characterized in that it being capsule, granule, tablet, watered pill, injection, ointment, spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021535159A CN1283303C (en) | 2002-12-02 | 2002-12-02 | Medicine composition for ischemia apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021535159A CN1283303C (en) | 2002-12-02 | 2002-12-02 | Medicine composition for ischemia apoplexy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1504221A CN1504221A (en) | 2004-06-16 |
| CN1283303C true CN1283303C (en) | 2006-11-08 |
Family
ID=34235173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021535159A Expired - Lifetime CN1283303C (en) | 2002-12-02 | 2002-12-02 | Medicine composition for ischemia apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1283303C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108938672B (en) * | 2018-09-27 | 2020-09-01 | 延边大学 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for rehabilitation treatment of ischemic cerebral apoplexy |
-
2002
- 2002-12-02 CN CNB021535159A patent/CN1283303C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1504221A (en) | 2004-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2596798B1 (en) | Plectranthus amboinicus fraction having anti-arthritis activity | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN100546615C (en) | Traditional Chinese medicine composition for treating cerebrovascular disease and preparation method thereof | |
| CN101152223B (en) | Application of poplar leaf phenolic extract in the preparation of medicine for treating arrhythmia | |
| CN110025664B (en) | Pharmaceutical composition for preventing and treating cerebral infarction and/or vascular dementia and application thereof | |
| CN1283303C (en) | Medicine composition for ischemia apoplexy | |
| CN111617193B (en) | Qinglong stopping particle | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN100444849C (en) | New use of tribulus terrestris extraction | |
| WO2022016827A1 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
| CN1899448A (en) | Chinese medicine compound preparation for treating amblyopia and its preparing method | |
| CN1279951C (en) | Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter | |
| CN1676143A (en) | Chinese medicine compound formulation for treating rheumatism | |
| CN117442677B (en) | Pharmaceutical composition for kidney injury and preparation method and application thereof | |
| CN118286310B (en) | Application of nux Prinsepiae or extract and composition thereof in treating and/or preventing liver injury | |
| CN1672722A (en) | A kind of heart-nourishing and tranquilizing medicine and preparation method thereof | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method | |
| CN1204916C (en) | Medicine for treating depression and its preparation method | |
| CN1141113C (en) | Chinese patent medicine for curing peptic ulcer | |
| WO2025218834A4 (en) | Medical use of loropetalum chinense or extract thereof | |
| CN100473410C (en) | Chinese medicinal preparation for treating apoplexy sequelae | |
| CN117982571A (en) | Application of Chuanxiong-Fructus Aurantii Immaturus drug pair composition in preparing medicine for treating ischemic stroke | |
| CN1768798A (en) | Medicine for promoting qi circulation, resolving food retention, benefiting stomach and stopping pain and preparation process thereof | |
| CN116370583A (en) | Traditional Chinese medicine composition for resisting depression and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WOHUA MEDICINE SCIENCE AND TECHNOLOGY CO., LTD., S Free format text: FORMER OWNER: BEIJING TIANTAIYUAN MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20121214 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100038 HAIDIAN, BEIJING TO: 261205 WEIFANG, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121214 Address after: 261205, 519, Liyuan street, hi tech Development Zone, Shandong, Weifang Patentee after: SHANDONG WOHUA PHARMACEUTICALS CO.,LTD. Address before: 100038, Beijing, Haidian District, 8 North honeycomb building, block A, 7 floor Patentee before: Beijing Tiantaiyuan Medicine Technology Development Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20061108 |